OptimizeRx (NASDAQ:OPRX) Now Covered by William Blair

William Blair started coverage on shares of OptimizeRx (NASDAQ:OPRX) in a report released on Thursday, January 3rd, MarketBeat reports. The brokerage set an “outperform” rating on the stock.

Several other research firms also recently commented on OPRX. Zacks Investment Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Lake Street Capital increased their target price on shares of OptimizeRx to $18.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Finally, Roth Capital upped their price target on shares of OptimizeRx from $22.50 to $25.00 and gave the company a “buy” rating in a report on Friday, September 28th. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $18.25.

OPRX opened at $12.98 on Thursday. The firm has a market capitalization of $159.67 million, a PE ratio of -61.81, a price-to-earnings-growth ratio of 2.85 and a beta of 0.92. OptimizeRx has a 12-month low of $2.30 and a 12-month high of $18.39.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Monday, November 5th. The company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.01. OptimizeRx had a net margin of 0.54% and a return on equity of 0.87%. The business had revenue of $5.42 million for the quarter, compared to the consensus estimate of $5.28 million. As a group, sell-side analysts expect that OptimizeRx will post 0.03 EPS for the current fiscal year.

A hedge fund recently bought a new stake in OptimizeRx stock. Vanguard Group Inc purchased a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 289,123 shares of the company’s stock, valued at approximately $5,204,000. Vanguard Group Inc owned 2.41% of OptimizeRx as of its most recent SEC filing. 33.72% of the stock is currently owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

See Also: Earnings Per Share (EPS) Explained

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply